GSK freezes HIV drug prices
Executive Summary
GlaxoSmithKline pledges not to increase list prices for its HIV products through January 2004 because of "a growing crisis" in funding for state AIDS Drug Assistance Programs. Company maintains that a growing number of newly diagnosed patients is contributing to the funding difficulties, especially in southern states. GSK has increased prices on its "backbone" antiretrovirals Retrovir, Epivir and Combivir by 28.7% since 1999...